



Fresenius Medical Care

P R E S S R E L E A S E

January 25, 2008
Bernd Ebeling
Corporate Communications
Tel.: +49-6172-6082378
Fax: +49-6172-6082294
e-mail: pr@fmc-ag.com
www.fmc-ag.com

Fresenius Medical Care Extends Senior Note Exchange Offer

Bad Homburg, Germany – Fresenius Medical Care AG & Co. KGaA (“the Company”) today announced that its wholly-owned subsidiary, FMC Finance III S.A. had extended the expiration date of its Exchange Offer to the holders of its 6-7/8% Senior Notes due 2017. The Notes will be unconditionally guaranteed by the Company, Fresenius Medical Care Holdings, Inc. and Fresenius Medical Care Deutschland GmbH. The Exchange Offer to holders of the Senior Notes will now expire at 5:00 p.m., New York City time, on February 7, 2008.

FMC Finance III S.A. is offering to exchange up to \$500,000,000 aggregate principal amount of 6-7/8% Senior Notes due 2017 which have been registered under the Securities Act of 1933 (“New Notes”) for a like principal amount of its outstanding 6-7/8% Senior Notes due 2017 (“Old Notes”). The Exchange Offer was originally scheduled to expire at midnight, New York time, on January 24, 2008.

At the close of business on January 24, 2008, approximately \$499,885,000 out of \$500,000,000 aggregate principal amount of Old Notes, including \$8,785,000 aggregate principal amount tendered by guaranteed delivery

procedures, have been received by U.S. Bank National Association, the Exchange Agent for the Exchange Offer.

The terms of the New Notes are identical in all material respects to the terms of the Old Notes, except for the elimination of certain transfer restrictions, registration rights and the conditional right to receive additional interest. The Exchange Offer is being made for all outstanding Old Notes and is not conditioned on any minimum principal amount of Old Notes being tendered for exchange.

###

Fresenius Medical Care is the world's largest integrated provider of products and services for individuals undergoing dialysis because of chronic kidney failure, a condition that affects more than 1,500,000 individuals worldwide. Through its network of 2,221 dialysis clinics in North America, Europe, Latin America, Asia-Pacific and Africa, Fresenius Medical Care provides dialysis treatment to 172,227 patients around the globe. Fresenius Medical Care is also the world's leading provider of dialysis products such as hemodialysis machines, dialyzers and related disposable products. Fresenius Medical Care is listed on the Frankfurt Stock Exchange (FME, FME3) and the New York Stock Exchange (FMS, FMS/P).

For more information about Fresenius Medical Care visit the Company's website at www.fmc-ag.com.

This release contains forward-looking statements that are subject to various risks and uncertainties. Actual results could differ materially from those described in these forward-looking statements due to certain factors, including uncertainties in the development of the home dialysis market, the ability to develop and commercialize technological innovations, changes in business, economic and competitive conditions, regulatory reforms, foreign exchange rate fluctuations, uncertainties in litigation or investigative proceedings, and the availability of financing. These and other risks and uncertainties are detailed in Fresenius Medical Care AG & Co. KGaA's reports filed with the U.S. Securities and Exchange Commission. Fresenius Medical Care AG & Co. KGaA does not undertake any responsibility to update the forward-looking statements in this release.